Effect of single-dose dexamethasone on acute phase response following zoledronic acid: a randomized controlled trial

[1] Black DM(2007)Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis N Engl J Med 356 1809-1822

[2] Delmas PD(2011)A single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5 years J Bone Miner Res 26 2261-2270

[3] Eastell R(2001)Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials J Clin Oncol 19 558-567

[4] Reid IR(2010)Prolonged antiresorptive activity of zoledronate: a randomized, controlled trial J Bone Miner Res 25 2251-2255

[5] Boonen S(2012)Five years of anti-resorptive activity after a single dose of zoledronate—results from a randomized double-blind placebo-controlled trial Bone 50 1389-1393

[6] Cauley JA(2012)Medication adherence and fracture risk among patients on bisphosphonate therapy in a large United States health plan Bone 50 870-875

[7] Cosman F(2010)Characterization of and risk factors for the acute-phase response after zoledronic acid J Clin Endocrinol Metab 95 4380-4387

[8] Lakatos P(2009)Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP Br J Haematol 144 245-250

[9] Leung PC(2012)Acute phase response following intravenous zoledronate in postmenopausal women with low bone mass Bone 50 1130-1134

[10] Man Z(2013)Monocytes and gammadelta T cells control the acute-phase response to intravenous zoledronate: insights from a phase IV safety trial J Bone Miner Res 28 464-471

[1] Black DM(2007)Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis N Engl J Med 356 1809-1822

[2] Delmas PD(2011)A single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5 years J Bone Miner Res 26 2261-2270

[3] Eastell R(2001)Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials J Clin Oncol 19 558-567

[4] Reid IR(2010)Prolonged antiresorptive activity of zoledronate: a randomized, controlled trial J Bone Miner Res 25 2251-2255

[5] Boonen S(2012)Five years of anti-resorptive activity after a single dose of zoledronate—results from a randomized double-blind placebo-controlled trial Bone 50 1389-1393

[6] Cauley JA(2012)Medication adherence and fracture risk among patients on bisphosphonate therapy in a large United States health plan Bone 50 870-875

[7] Cosman F(2010)Characterization of and risk factors for the acute-phase response after zoledronic acid J Clin Endocrinol Metab 95 4380-4387

[8] Lakatos P(2009)Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP Br J Haematol 144 245-250

[9] Leung PC(2012)Acute phase response following intravenous zoledronate in postmenopausal women with low bone mass Bone 50 1130-1134

[10] Man Z(2013)Monocytes and gammadelta T cells control the acute-phase response to intravenous zoledronate: insights from a phase IV safety trial J Bone Miner Res 28 464-471